Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine

被引:24
作者
Brave, Andreas
Ljungberg, Karl
Boberg, Andreas
Rollman, Erik
Engstrom, Gunnel
Hinkula, Jorma
Wahren, Britta [1 ]
机构
[1] Swedish Inst Infect Dis Control, Dept Virol, S-17182 Solna, Sweden
[2] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden
[3] Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27599 USA
关键词
DNA vaccination; multivalent vaccine; HIV-1;
D O I
10.1016/j.vaccine.2005.08.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the effects of immunizing with several genes and subtypes of HIV-1. The genes used as immunogens were: gp 160 envelope (env subtypes A, B and Q, p37gag (gag subtypes A and 13), rev (subtype 13) and reverse transcriptase (RT subtype 13). The different genes are all carried by separate plasmids. C5713L/6 and BALB/c mice were immunized with different combinations of the genes together with recombinant cytokine granulocyte macrophage-colony stimulating factor. The env genes injected alone induced significantly stronger cellular responses to envelope in both strains of mice than when env genes were injected together with gag and RT genes. In the C5713L/6 mice, the envelope specific responses were significantly increased after spatial separation of env genes from gag and RT genes as compared to when all vaccine genes were injected as a mixture. The gag responses were strong in gag-immunized animals and were not significantly affected by the spatial separation of gag and RT genes from the env genes. Our results illustrate the importance of being cautious when formulating multivalent genetic vaccines and that it might be possible to overcome lost immune responses through spatial separation of vaccine antigens. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4524 / 4526
页数:3
相关论文
共 9 条
[1]  
BRAVE A, 2004, RATIONAL DESIGN VACC
[2]   Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered [J].
Daum, RS ;
Zenko, CE ;
Given, GZ ;
Ballanco, GA ;
Parikh, H ;
Germino, K .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (10) :1293-1299
[3]   Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants [J].
DiezDelgado, J ;
DalRe, R ;
Llorente, M ;
Gonzalez, A ;
Lopez, J .
VACCINE, 1997, 15 (12-13) :1418-1422
[4]   DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge [J].
Isaguliants, MG ;
Petrakova, N ;
Zuber, B ;
Pokrovskaya, K ;
Gizatullin, R ;
Kostyuk, DA ;
Kjerrström, A ;
Winberg, G ;
Kochetkov, SN ;
Hinkula, J ;
Wahren, B .
INTERVIROLOGY, 2000, 43 (4-6) :288-293
[5]   Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines [J].
Kjerrström, A ;
Hinkula, J ;
Engström, G ;
Ovod, V ;
Krohn, K ;
Benthin, R ;
Wahren, B .
VIROLOGY, 2001, 284 (01) :46-61
[6]   Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen [J].
Leung, L ;
Srivastava, IK ;
Kan, E ;
Legg, H ;
Sun, Y ;
Greer, C ;
Montefiori, DC ;
Megede, JZ ;
Barnett, SW .
AIDS, 2004, 18 (07) :991-1001
[7]   Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes [J].
Ljungberg, K ;
Rollman, E ;
Eriksson, L ;
Hinkula, J ;
Wahren, B .
VIROLOGY, 2002, 302 (01) :44-57
[8]   Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF [J].
Sedegah, M ;
Charoenvit, Y ;
Aguiar, J ;
Sacci, J ;
Hedstrom, R ;
Kumar, S ;
Belmonte, A ;
Lanar, DE ;
Jones, TR ;
Abot, E ;
Druilhe, P ;
Corradin, G ;
Epstein, JE ;
Richie, TL ;
Carucci, DJ ;
Hoffman, SL .
GENES AND IMMUNITY, 2004, 5 (07) :553-561
[9]   Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA [J].
Zuber, AK ;
Bråve, A ;
Engström, G ;
Zuber, B ;
Ljungberg, K ;
Fredriksson, M ;
Benthin, R ;
Isaguliants, MG ;
Sandström, E ;
Hinkula, J ;
Wahren, B .
VACCINE, 2004, 22 (13-14) :1791-1798